**Supplemental table 7: Development of metastatic disease after initial presentation with non-metastatic neuroendocrine neoplasms for different primary origins (cohort reference network)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | All (%) | GE (%) | Pancreas (%) | Lung (%) | Other (%) | Unknown (%) |
| Non-metastatic at diagnosis | 279 | 121 | 56 | 48 | 54 | 0 |
| New metastases | 64 (23) | 19 (16) | 9 (16) | 12 (25) | 24 (44) | 0 |
| Location metastatic disease |  |  |  |  |  |  |
| Liver | 25 (9) | 8 (7) | 7 (13) | 5 (10) | 5 (9) | 0 |
| Brain | 3 (1) | 0 (0) | 0 (0) | 1 (2) | 2 (4) | 0 |
| Lung | 8 (3) | 2 (2) | 0 (0) | 3 (6) | 3 (6) | 0 |
| Bone | 20 (7) | 9 (7) | 0 (0) | 4 (8) | 8 (15) | 0 |
| Lymph nodes (distant) | 33 (12) | 13 (11) | 4 (7) | 2 (4) | 14 (26) | 0 |
| Peritoneal | 6 (2) | 4 (3) | 1 (2) | 0 (0) | 1 (2) | 0 |
| Other | 10 (4) | 2 (2) | 1 (2) | 1 (2) | 6 (11) | 0 |

*Abbreviations: GE = gastroenteral.*